Affiliation:
1. “Moscow Clinical Scientific Center named after A. S. Loginov”; State Budgetary Institution “Research Institute for Healthcare
Organization and Medical Management of Moscow Healthcare Department”;Federal State Budgetary Institution “National Medical Research Center of Coloproctology named after A. N. Ryzhikh”
2. “Moscow Clinical Scientific Center named after A. S. Loginov”
3. State Budgetary Institution “Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare
Department”
4. State Budget Institution “The Research Institute of Health Care organization and Medical Management of the Moscow Health Care Department”
Abstract
Background and purpose. The aim of this work is to evaluate the efficacy of treatment patients with moderate left-sided and total ulcerative colitis (UC) with prolonged-release ethylcellulose-coated mesalazine. Materials and methods. The clinical analyses of results of treatment UC patients with prolonged-release ethylcellulose-coated mesalazine was performed. Eighty-seven patients with UC, treated with ethylcellulose coated microgranules of mesalazine, were examined: 38 (43,7%) men and 49 (56,3%) women. The age of patients was from 26 to 49 years, median age 38,3±12,6 year. Results. After 2 weeks prolonged-release ethylcellulose coated mesalazine treatment the response to therapy was demonstrated in majority of UC patients -71 (81,6%). After 12 weeks treatment prolonged remission persisted in 71 (81,6%) UC patients. Mayo score decreased from 7,6±0,99 to 2,6±0,25 points. Significant decrease of inflammation markers (CRP, ESR, leukocytosis, fecal calprotectin etc) was determined. After 26 weeks of treatment Mayo score was 2,2-2,3 points. Thirty-two (36,8%) UC patients showed healing of colon mucosa. After 1 year of prolonged-release ethylcellulose-coated mesalazine treatment clinical remission was determined in 69 (79,3%) UC patients with response to therapy, clinical-endoscopic remission — in 32 (36,8%) patients. During 1 year follow-up no cases of surgical procedure and readmission because of UC reccurence were noted. Conclusion. Treatment of moderate active UC should be started with oral mesalazine > 3 gr per day and rectal mesalazine. The most appropriate effective and high compliance forms of mesalazine are prolonged-release forms of meselazine.
Publisher
Research Institute for Healthcare Organization and Medical Management
Reference25 articles.
1. Inflammatory bowel diseases in surgery and therapeutical clinical practice : [monograph] / Hatkov IE, Parfenov AI, Knyazev OV [et al.]; Moscow Clinical Scientific Centre (MCSC). Мoscow: VITA-PRESS, 2017, 119 p. ISBN 978-5-7755-3680-0 (In Russ.).
2. M'koma A. Inflammatory Bowel Disease: An Expanding Global Health Problem. Clinical Medicine Insights: Gastroenterology. 2013;6:CGast.S12731. doi:10.4137/cgast.s12731
3. Ng S, Shi H, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390(10114):2769-2778. doi: 10.1016/s0140-6736(17)32448-0
4. Knyazev O, Shkurko T, Kagramanova A, Veselov A, Nikonov E. Epidemiology of inflammatory bowel disease. State of the problem (review). Dokazatel'naya gastroenterologiya. 2020;9(2):66-73 (In Russ.). doi: 10.17116/dokgastro2020902166
5. Nikulina IV, Zlatkina АR, Belousova EA, Rumyantsev YG, Yurkov МU. Assessment of clinical-epidemiological parameters of inflammatory bowel diseases in Moscow region Russian Journal of gastroenterology, hepatology, coloproctology. 1997;2:67-71 (In Russ.).